Jaguar Animal Health says Neonorm foal study accepted for publication
Jaguar Animal Health and Napo Pharmaceuticals, which focuses on the development and commercialization of proprietary gastrointestinal pharmaceuticals for the global marketplace from sustainably derived plants used traditionally in rainforest areas, announced that an Argentina-based study titled "Safety and efficacy of a combined paste formulation of Neonorm Foal, a botanical extract of the latex of Croton lechleri, and probiotics for the treatment of watery diarrhea in nursing foals" has been accepted for publication by Analecta Veterinaria, a bi-annual, peer-reviewed publication of the Faculty of Veterinary Sciences of the National University of La Plata in Argentina. The study objective was to evaluate the safety, tolerability, and efficacy of Neonorm Foal for treatment of foals suffering from secretory or watery diarrhea. Sixty foals participated in the study, which consisted of a 72-hour treatment period followed by an observation period. The treated animals received NeonormFoal in combination with a third-party probiotic. The percentage of responders from 0-72 hours was greater in the IVP BID group than in the placebo group with a p value of 0.03. The percentage of responders from 0-96 hours was also found to be greater in IVP BID group when compared to the placebo group with a p value of 0.03. From 0-120 hours, the percentage of responders in the IVP QID group was 84% versus 53% in the placebo group, which was found to be significant with a p value of 0.04.